Juan C Troncoso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2180911/publications.pdf

Version: 2024-02-01

36303 24258 14,401 126 51 110 citations h-index g-index papers 137 137 137 21769 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	7.7	19
2	Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer's Disease. Cells, 2022, 11, 436.	4.1	18
3	Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological α-synuclein. Cell Reports, 2022, 38, 110358.	6.4	18
4	Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinson's disease. Science Advances, 2022, 8, eabh1824.	10.3	12
5	Activated endothelial cells induce a distinct type of astrocytic reactivity. Communications Biology, 2022, 5, 282.	4.4	19
6	STING mediates neurodegeneration and neuroinflammation in nigrostriatal \hat{l} ±-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2118819119.	7.1	64
7	Quantitative proteomic analysis of the frontal cortex in Alzheimer's disease. Journal of Neurochemistry, 2021, 156, 988-1002.	3.9	32
8	Persistently Elevated mTOR Complex 1-S6 Kinase 1 Disrupts DARPP-32–Dependent D1 Dopamine Receptor Signaling and Behaviors. Biological Psychiatry, 2021, 89, 1058-1072.	1.3	8
9	Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2021, 29, 958-968.	1.2	17
10	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	1.7	35
11	GDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein. Science Translational Medicine, 2021, 13, .	12.4	12
12	NMDA Receptor Antagonism for Neuroprotection in a Canine Model of Hypothermic Circulatory Arrest. Journal of Surgical Research, 2021, 260, 177-189.	1.6	2
13	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. Acta Neuropathologica Communications, 2021, 9, 78.	5.2	82
14	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. PLoS Medicine, 2021, 18, e1003615.	8.4	38
15	Abnormal brain cholesterol homeostasis in Alzheimer's diseaseâ€"a targeted metabolomic and transcriptomic study. Npj Aging and Mechanisms of Disease, 2021, 7, 11.	4.5	59
16	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. Neuron, 2021, 109, 3758-3774.e11.	8.1	26
17	A brain proteomic signature of incipient Alzheimer's disease in young <i>APOE</i> Îμ4 carriers identifies novel drug targets. Science Advances, 2021, 7, eabi8178.	10.3	23
18	Influence of species and processing parameters on recovery and content of brain tissueâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2020, 9, 1785746.	12.2	72

#	Article	IF	Citations
19	A consensus proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Alzheimer's and Dementia, 2020, 16, e039504.	0.8	0
20	Shared proteomic effects of cerebral atherosclerosis and Alzheimer's disease on the human brain. Nature Neuroscience, 2020, 23, 696-700.	14.8	86
21	Multiplexed Phosphoproteomic Study of Brain in Patients with Alzheimer's Disease and Age-Matched Cognitively Healthy Controls. OMICS A Journal of Integrative Biology, 2020, 24, 216-227.	2.0	22
22	Diffeomorphic Registration With Intensity Transformation and Missing Data: Application to 3D Digital Pathology of Alzheimer's Disease. Frontiers in Neuroscience, 2020, 14, 52.	2.8	31
23	Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study. PLoS Medicine, 2020, 17, e1003012.	8.4	90
24	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780.	30.7	547
25	Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington's disease. Human Molecular Genetics, 2020, 29, 1340-1352.	2.9	10
26	Mapping tracts in the human subthalamic area by 11.7T ex vivo diffusion tensor imaging. Brain Structure and Function, 2020, 225, 1293-1312.	2.3	17
27	$\hat{l}\pm$ -Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Molecular Neurodegeneration, 2020, 15, 27.	10.8	35
28	Discovery of several thousand highly diverse circular DNA viruses. ELife, 2020, 9, .	6.0	131
29	C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathologica, 2019, 138, 795-811.	7.7	50
30	Expanding the Computational Anatomy Gateway from clinical imaging to basic neuroscience research. , 2019, , .		0
31	Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 28.	6.2	27
32	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
33	Constitution and applying of diagnosad Alphaimavi-FTMa diagnos identifies now viables and implicator Air tou		
	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
34		21.4	1,962
34	immunity and lipid processing. Nature Genetics, 2019, 51, 414-430. The "Race―Toward Diversity, Inclusion, and Equity in Pathology: The Johns Hopkins Experience.		

#	Article	IF	CITATIONS
37	PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1686-1691.	7.1	140
38	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
39	Discrete Pools of Oligomeric Amyloid-β Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. American Journal of Pathology, 2018, 188, 739-756.	3.8	16
40	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
41	Domainâ€specific cognitive impairment in nonâ€demented Parkinson's disease psychosis. International Journal of Geriatric Psychiatry, 2018, 33, e131-e139.	2.7	9
42	Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 318-329.	0.8	320
43	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
44	Discovery of noncanonical translation initiation sites through mass spectrometric analysis of protein N termini. Genome Research, 2018, 28, 25-36.	5.5	75
45	Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Movement Disorders Clinical Practice, 2018, 5, 31-38.	1.5	9
46	P3â€451: QUANTIFICATION OF 3D TANGLE DISTRIBUTION IN MEDIAL TEMPORAL LOBE USING MULTIMODAL IMAGE REGISTRATION AND CONVOLUTIONAL NEURAL NETWORKS. Alzheimer's and Dementia, 2018, 14, P1291.	0.8	1
47	Amyloid \hat{I}^2 toxic conformer has dynamic localization in the human inferior parietal cortex in absence of amyloid plaques. Scientific Reports, 2018, 8, 16895.	3.3	15
48	Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Molecular Neurodegeneration, 2018, 13, 52.	10.8	178
49	Abnormal CSF amyloid- \hat{l}^2 42 and tau levels in hip fracture patients without dementia. PLoS ONE, 2018, 13, e0204695.	2.5	19
50	P2â€⊋76: BRAIN AND BLOOD OXYSTEROL METABOLISM ARE RELATED TO ALZHEIMER'S DISEASE PATHOGENESIS Alzheimer's and Dementia, 2018, 14, P783.	0.8	0
51	Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease. Science, 2018, 362, .	12.6	317
52	Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron, 2018, 99, 925-940.e7.	8.1	302
53	<pre><scp>SCA</scp> 8 <scp>RAN</scp> polySer protein preferentially accumulates in white matter regions and is regulated by <scp>elF</scp> 3F. EMBO Journal, 2018, 37, .</pre>	7.8	50
54	The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype. Neurobiology of Aging, 2018, 71, 72-80.	3.1	42

#	Article	IF	CITATIONS
55	Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Medicine, 2018, 15, e1002482.	8.4	336
56	Expression of mutant DISC1 in Purkinje cells increases their spontaneous activity and impairs cognitive and social behaviors in mice. Neurobiology of Disease, 2017, 103, 144-153.	4.4	17
57	Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron, 2017, 94, 93-107.e6.	8.1	274
58	Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathologica, 2017, 133, 923-931.	7.7	58
59	<i>ADORA1</i> mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies. Movement Disorders, 2017, 32, 298-299.	3.9	11
60	A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. Cell Systems, 2017, 4, 60-72.e4.	6.2	381
61	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
62	[P3–207]: THE ENDOPHENOTYPE ASSOCIATION SCORE IN EARLY ALZHEIMER's DISEASE (EASEâ€AD): DISCOVERING NOVEL BLOOD AND BRAIN METABOLITE SIGNATURES OF PATHOLOGY AND PROGRESSION. Alzheimer's and Dementia, 2017, 13, P1015.	0.8	0
63	[P3–166]: NEUROTRANSMITTERâ€SPECIFIC METABOLISM IS RELATED TO SEVERITY OF PATHOLOGY AND SYMPTOM EXPRESSION IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P997.	0.8	0
64	MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. Frontiers in Molecular Neuroscience, 2017, 10, 329.	2.9	43
65	NPTX2 and cognitive dysfunction in Alzheimer's Disease. ELife, 2017, 6, .	6.0	146
66	Ventricular and Periventricular Anomalies in the Aging and Cognitively Impaired Brain. Frontiers in Aging Neuroscience, 2017, 9, 445.	3.4	33
67	Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models. Oncotarget, 2017, 8, 106721-106739.	1.8	13
68	TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. ELife, 2016, 5,	6.0	97
69	Rhoâ \in associated protein kinase 1 ($<$ scp $>$ ROCK $<$ /scp $>$ 1) is increased in Alzheimer's disease and $<$ scp $>$ ROCK $<$ /scp $>$ 1 depletion reduces amyloidâ \in \hat{I} 2 levels in brain. Journal of Neurochemistry, 2016, 138, 525-531.	3.9	97
70	Clinicopathological correlates of depression in early Alzheimer's disease in the NACC. International Journal of Geriatric Psychiatry, 2016, 31, 1301-1311.	2.7	27
71	Transcriptome sequencing reveals aberrant alternative splicing in Huntington's disease. Human Molecular Genetics, 2016, 25, 3454-3466.	2.9	102
72	P2â€106: Brain and Blood Metabolite Signatures of Pathology and Progression in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P652.	0.8	0

#	Article	IF	Citations
7 3	P2â€294: The Acute Phase Protein Alphaâ€2â€Macroglobulin Predicts Risk of Incident Alzheimer's Disease and Modulates TAU Pathology through the RCAN1â€Calcineurin Pathway. Alzheimer's and Dementia, 2016, 12, P745.	0.8	0
74	Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 33, 102-106.	2.2	8
7 5	Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression. Proteomics, 2016, 16, 3042-3053.	2.2	69
76	Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model. Neuron, 2016, 92, 407-418.	8.1	120
77	Quantitative Proteomic Analysis Reveals Similarities between Huntington's Disease (HD) and Huntington's Disease-Like 2 (HDL2) Human Brains. Journal of Proteome Research, 2016, 15, 3266-3283.	3.7	32
78	A culture–brain link: Negative age stereotypes predict Alzheimer's disease biomarkers Psychology and Aging, 2016, 31, 82-88.	1.6	138
79	Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nature Communications, 2016, 7, 11792.	12.8	56
80	A rapidly progressive dementia case with pathological diagnosis of FTLD-UPS. Acta Neuropathologica, 2016, 132, 309-311.	7.7	0
81	Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiology of Disease, 2016, 94, 55-62.	4.4	55
82	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380
83	Adult Conditional Knockout of PGC-1α Leads to Loss of Dopamine Neurons. ENeuro, 2016, 3, ENEURO.0183-16.2016.	1.9	87
84	P1-207: Alzheimer's lesions in the brains of young subjects., 2015, 11, P429-P429.		0
85	P4-187: Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology, and presymptomatic cerebral amyloid accumulation., 2015, 11, P851-P852.		1
86	Neuropathology and <scp>C</scp> ellular <scp>P</scp> athogenesis of <scp>S</scp> pinocerebellar <scp>A</scp> taxia <scp>T</scp> ype 12. Movement Disorders, 2015, 30, 1813-1824.	3.9	32
87	Altered CSMD1 Expression Alters Cocaine-Conditioned Place Preference: Mutual Support for a Complex Locus from Human and Mouse Models. PLoS ONE, 2015, 10, e0120908.	2.5	5
88	Cannabinoid CB2 Receptors in a Mouse Model of ${\rm A\hat{l}^2}$ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. PLoS ONE, 2015, 10, e0129618.	2.5	83
89	Lysosomal Enzyme Glucocerebrosidase Protects against AÎ 2 1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854.	2.5	12
90	Mouse Model for Protein Tyrosine Phosphatase D (PTPRD) Associations with Restless Leg Syndrome or Willis-Ekbom Disease and Addiction: Reduced Expression Alters Locomotion, Sleep Behaviors and Cocaine-Conditioned Place Preference. Molecular Medicine, 2015, 21, 717-725.	4.4	45

#	Article	IF	Citations
91	O4-12-02: Protein co-expression network analysis in Alzheimer's disease., 2015, 11, P299-P299.		0
92	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
93	TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science, 2015, 349, 650-655.	12.6	419
94	Probing region-specific microstructure of human cortical areas using high angular and spatial resolution diffusion MRI. NeuroImage, 2015, 105, 198-207.	4.2	73
95	APOÎ μ 2 and education in cognitively normal older subjects with high levels of AD pathology at autopsy: findings from the Nun Study. Oncotarget, 2015, 6, 14082-14091.	1.8	11
96	Aggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease. Journal of Biological Chemistry, 2014, 289, 35296-35313.	3.4	42
97	Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Human Molecular Genetics, 2014, 23, 4621-4638.	2.9	126
98	The problem of axonal injury in the brains of veterans with histories of blast exposure. Acta Neuropathologica Communications, 2014, 2, 153.	5.2	77
99	Mild Cognitive Impairment and Asymptomatic Alzheimer Disease Subjects. Journal of Neuropathology and Experimental Neurology, 2014, 73, 295-304.	1.7	55
100	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
101	C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature, 2014, 507, 195-200.	27.8	779
102	Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of Aging, 2014, 35, 2419.e17-2419.e21.	3.1	21
103	HuD Regulates Coding and Noncoding RNA to Induce APPâ†'Aβ Processing. Cell Reports, 2014, 7, 1401-1409.	6.4	90
104	Hippocampal sclerosis dementia: An amnesic variant of frontotemporal degeneration. Dementia E Neuropsychologia, 2013, 7, 83-87.	0.8	13
105	Neuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA). Journal of Alzheimer's Disease, 2009, 18, 665-675.	2.6	122
106	Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Annals of Neurology, 2008, 64, 168-176.	5.3	203
107	Neuronal hypertrophy in asymptomatic Alzheimer's Disease in the BLSA. FASEB Journal, 2008, 22, 707.1.	0.5	0
108	Primary angiitis of the central nervous system presenting as chronic superior sagittal sinus thrombosis. FASEB Journal, 2007, 21, A396.	0.5	0

#	Article	IF	Citations
109	Differential nuclear and nucleolar hypertrophy of anterior and posterior cingulate neurons in asymptomatic subjects with AD pathology. FASEB Journal, 2007, 21, A19.	0.5	0
110	Biotinylated antiâ€Aβ antibody as a tool to diagnose pre linical stages of Alzheimer's Disease (AD). FASEB Journal, 2007, 21, A20.	0.5	0
111	Papillomavirus-Like Particles Are an Effective Platform for Amyloid- \hat{I}^2 Immunization in Rabbits and Transgenic Mice. Journal of Immunology, 2006, 177, 2662-2670.	0.8	52
112	Neuronal cell death in human neurodegenerative diseases and their animal/cell models. , 2005, , 96-155.		1
113	A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Annals of Neurology, 2001, 50, 373-380.	5.3	104
114	A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Annals of Neurology, 2001, 50, 373-380.	5.3	155
115	<i>\(\hat{i}^2<\i\hat{i}\)-Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain A<i\hat{i}^2<\i\hat{i}\) 20,="" 2001,="" 713-721.<="" and="" appswe="" as="" biology,="" by="" cell="" detected="" dna="" in="" levels="" mice,="" proteinchip<\(\hat{sup}\)\(\hat{a}^0<\\hat{sup}\)="" ps1\(\hat{i}\)"e9="" seldi-tof-based="" td="" technology.=""><td>1.9</td><td>46</td></i\hat{i}^2<\i\hat{i}\)></i>	1.9	46
116	Decreasing Incidence of Sudden Death Due to Undiagnosed Primary Central Nervous System Tumors. Archives of Pathology and Laboratory Medicine, 2001, 125, 1024-1030.	2.5	31
117	Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Annals of Neurology, 1999, 46, 325-332.	5.3	140
118	Neuropathology of preclinical and clinical lateonset Alzheimer's disease. Annals of Neurology, 1998, 43, 673-676.	5.3	83
119	Loss of the Presynaptic Vesicle Protein Synaptophysin in Hippocampus Correlates with Cognitive Decline in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1997, 56, 933-944.	1.7	487
120	Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature, 1995, 378, 284-287.	27.8	222
121	Phosphorylation Modulates Calpain-Mediated Proteolysis and Calmodulin Binding of the 200-kDa and 160-kDa Neurofilament Proteins. Journal of Neurochemistry, 1993, 61, 191-199.	3.9	86
122	Altered excitatory and inhibitory amino acid receptor binding in hippocampus of patients with temporal lobe epilepsy. Annals of Neurology, 1991, 29, 529-541.	5.3	217
123	Bilateral opercular polymicrogyria. Annals of Neurology, 1989, 25, 90-92.	5.3	81
124	Neurofilamentous Abnormalities in Motor Neurons in Spontaneously Occurring Animal Disorders. Journal of Neuropathology and Experimental Neurology, 1988, 47, 420-431.	1.7	55
125	Neurofibrillary axonal pathology in aluminum intoxication. Annals of Neurology, 1982, 12, 278-283.	5.3	106
126	Canine inherited ataxia. Annals of Neurology, 1981, 9, 492-498.	5.3	25